Ascendis Pharma A/S Announces R&D Update to Review Expanded Pipeline and Long-term Strategic Outlook
The event will feature an overview of Ascendis' Vision 20/20 to build a leading, commercially-integrated, rare disease company addressing significant unmet medical needs.
Presentations by outside experts and Ascendis senior management will highlight the market opportunity, product profiles, data and development plans for TransCon Growth Hormone, as well as for two new rare disease endocrinology product candidates.
R&D Update Event Information |
|
Date: |
Friday, September 30, 2016 |
Time: |
8:30 a.m. - 11:30 a.m. ET (Registration to begin at 8:00 a.m. ET) |
Location: |
New York, NY |
If you are a member of the investment community and would like to attend, please send an email to ir@ascendispharma.com to receive additional information.
A live webcast of the R&D Update will be made available on the Investors & News section of the
About
Additionally,
The TransCon technology combines the benefits of prodrug and sustained release technologies, and is the key driver of
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our product pipeline, (ii) our plan to become a leading, commercially-integrated, rare disease company, (iii) the market opportunity, product profiles, data and development plans for TransCon Growth Hormone , (iv) the market opportunity, product profiles, data and development plans for any potential new rare disease endocrinology product candidates, and (v) the application of our TransCon technology to the creation of product candidates to address significant unmet medical needs in rare disease indications carrying substantial commercial potential. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our lead development program TransCon Growth Hormone or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the
Internal contact:
Chief Financial Officer
(650) 352-8389
ir@ascendispharma.com
Investor contact:
Westwicke Partners
(415) 513-1284
patti.bank@westwicke.com
Media contact:
SparkBioComm
(650) 739-9952
ami@sparkbiocomm.com
Logo - http://photos.prnewswire.com/prnh/20150824/260617LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ascendis-pharma-as-announces-rd-update-to-review-expanded-pipeline-and-long-term-strategic-outlook-300313622.html
SOURCE